. 2004 Dec 31;54(9):826–836. doi: 10.1007/s00262-004-0650-5

Table 3.

Expression analysis, known T-cell epitopes, and novel HLA ligands of reported RCC-associated antigens

RCC-associated tumor antigen overexpression > threefold in X/11 RCCs	Entrez Gene ID	Known T-cell epitopes	HLA restriction	References	Peptides found in this study
Met proto-oncogene (MET) 11/11 (M 12.3; R 4.3–28.3)	4233	YVDPVITSI	A*02	[43]	YVDPVITSI (A*02) [56]
Carbonic anhydrase isoform 9 (CA9) 7/11 (M 4.0; R 0.4–11.3)	768	HLSTAFARV	A*02	[53]	SPRAAEPVQL (B*07)
Adipose differentiation-related protein (ADFP) 5/11 (M 2.6; R 0.1–5.5)	123	SVASTITGV	A*02	[45]	See Table 2
Cyclin D1 (CCND1) 4/11 (M 1.8; R 0.7–5.7)	595	RLTRFLSRV	A*02 (allo)	[42]	ETIPLTAEKL (A*6801) [56]
		LLGATCMFV	A*02 (allo)	[42]
Survivin (BIRC5) 3/11 (M 1.4; R 0.4–0.9)	332	ELTLGEFLKL	A*02	[46]
Preferentially expressed antigen in melanoma (PRAME) 2/11 (M 0.4; R 0.1–4.7)	23532	SLLQHLIGL	A*02	[25]
		ALYVDSLFFL	A*02	[25]
		VLDGLDVLL	A*02	[25]
		SLYSFPEPEA	A*02	[25]
		LYVDSLFFL	A*24	[19]
Melanoma antigen, family A, 3 (MAGEA3) 1/11 (M 1.3; R 0.4–6.2)	4102	FLWGPRALV	A*02	[12, 52]
		KVAELVHFL	A*0201	[24]
		EVDPIGHLY	A01, B35	[7, 47]
		IMPKAGLLI	A*24	[51]
		TFPDLESEF	A*2402	[31]
		MEVDPIGHLY	B*44	[16]
Renal tumor antigen (RAGE) 0/11 (M 0.6; R 0.4–1.3)	5891	PASKKTDPQK	B*08	[11]
Renal tumor antigen (RAGE) 0/11 (M 0.6; R 0.4–1.3)	5891	SPSSNRIRNT	B*07	[14]
Cancer/testis antigen 1B (NY-ESO-1) 0/11 (M 0.7; R 0.5–2.6)	1485	SLLMWITQC	A*0201	[21]
Melanoma antigen, family A, 1 (MAGEA1) 0/11 (M 0.1; R 0.0–0.6)	4100	KVLEYVIKV and many others	A*0201	[37]
Mucin 1 (MUC1) 0/11 (M 0.4; R 0.1–0.8)	4582	LLLLTVLTV	A*02	[4]
Mucin 1 (MUC1) 0/11 (M 0.4; R 0.1–0.8)	4582	STAPPVHNV and others	A*0201	[4, 2]
Telomerase reverse transcriptase (TERT) 0/11 (M 0.6; R 0.5–1.5)	7015	ILAKFLHWL	A*0201	[55]
		KLFGVLRLK	A*03	[54]
		VYGFVRACL	A*2402	[3]
		VYAETKHFL	A*2402	[3]

M median; R range of overexpression